Alpha Cognition (NASDAQ:ACOG) Coverage Initiated by Analysts at Maxim Group

Equities research analysts at Maxim Group assumed coverage on shares of Alpha Cognition (NASDAQ:ACOG) in a report released on Friday. The brokerage set a “buy” rating and a $12.00 price target on the stock. Maxim Group’s target price points to a potential upside of 102.02% from the company’s current price.

A number of other equities research analysts have also commented on ACOG. Wall Street Zen lowered Alpha Cognition from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Alpha Cognition in a research report on Friday, May 22nd. Finally, Craig Hallum started coverage on Alpha Cognition in a research report on Friday, April 17th. They set a “buy” rating and a $14.00 price objective for the company. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $14.67.

Alpha Cognition Stock Up 3.7%

NASDAQ:ACOG opened at $5.94 on Friday. Alpha Cognition has a 1-year low of $4.50 and a 1-year high of $11.54. The firm has a market capitalization of $129.31 million, a price-to-earnings ratio of -4.40 and a beta of 2.38. The stock has a fifty day simple moving average of $6.07 and a 200 day simple moving average of $5.90.

Alpha Cognition (NASDAQ:ACOG) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.04. Alpha Cognition had a negative return on equity of 58.35% and a negative net margin of 232.23%.The business had revenue of $3.53 million during the quarter, compared to analyst estimates of $3.42 million. Equities analysts predict that Alpha Cognition will post -1.34 earnings per share for the current year.

Institutional Investors Weigh In On Alpha Cognition

Several institutional investors have recently made changes to their positions in the company. Aristides Capital LLC lifted its holdings in shares of Alpha Cognition by 1.4% during the 1st quarter. Aristides Capital LLC now owns 218,510 shares of the company’s stock valued at $1,200,000 after buying an additional 3,052 shares during the last quarter. Berkshire Asset Management LLC PA lifted its holdings in shares of Alpha Cognition by 50.7% during the 3rd quarter. Berkshire Asset Management LLC PA now owns 17,824 shares of the company’s stock valued at $116,000 after buying an additional 6,000 shares during the last quarter. Villere ST Denis J & Co. LLC lifted its holdings in shares of Alpha Cognition by 13.2% during the 4th quarter. Villere ST Denis J & Co. LLC now owns 73,875 shares of the company’s stock valued at $480,000 after buying an additional 8,617 shares during the last quarter. Green Alpha Advisors LLC acquired a new stake in shares of Alpha Cognition during the 4th quarter valued at about $72,000. Finally, Geode Capital Management LLC acquired a new stake in shares of Alpha Cognition during the 2nd quarter valued at about $112,000.

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.